Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 4Myelodysplastic Syndromes 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell 1Lymphoma, B-Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Biphenotypic, Acute 1Hodgkin Disease 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 11ruxolitinib 10fludarabine phosphate 9Tacrolimus 7Filgrastim 7fludarabine 6Decitabine 6Whole-Body Irradiation 5Peripheral Blood Stem Cell Transplantation 5Mycophenolic Acid 5Busulfan 5navitoclax 4Sirolimus 4Etoposide 4Azacitidine 4Specimen Handling 3Methylprednisolone 3Methotrexate 3Melphalan 3Cyclosporine 3Antilymphocyte Serum 3venetoclax 2thymoglobulin 2durvalumab 2Vorinostat 2Thiotepa 2Sunitinib 2Stem Cell Transplantation 2Radiotherapy 2Prednisone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Primary Myelofibrosis × tagraxofusp × Clear all
NCT05233618 2025-05-28

Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)

University of Virginia

Phase 1 Recruiting
44 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡